GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.58 MXN | +3.55% |
|
-5.69% | +2.97% |
| Mar. 13 | Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend | CI |
| Feb. 22 | Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024 |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.97% | 764M | B+ | ||
| +24.60% | 672B | C+ | ||
| +24.08% | 550B | B | ||
| -5.63% | 351B | C+ | ||
| +15.37% | 317B | B- | ||
| +7.38% | 292B | C+ | ||
| +3.26% | 211B | B+ | ||
| +0.78% | 203B | B- | ||
| -9.69% | 144B | C+ | ||
| -6.63% | 141B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LAB B Stock
- Ratings Genomma Lab Internacional, S.A.B. de C.V.
